Neurosurg Focus. 2019 Mar 1;46(3):E10. doi: 10.3171/2018.12.FOCUS18602.
Recent advances in stem cell biology present significant opportunities to advance clinical applications of stem cell-based therapies for spinal cord injury (SCI). In this review, the authors critically analyze the basic science and translational evidence that supports the use of various stem cell sources, including induced pluripotent stem cells, oligodendrocyte precursor cells, and mesenchymal stem cells. They subsequently explore recent advances in stem cell biology and discuss ongoing clinical translation efforts, including combinatorial strategies utilizing scaffolds, biogels, and growth factors to augment stem cell survival, function, and engraftment. Finally, the authors discuss the evolution of stem cell therapies for SCI by providing an overview of completed (n = 18) and ongoing (n = 9) clinical trials.
干细胞生物学的最新进展为推进基于干细胞的脊髓损伤 (SCI) 治疗的临床应用提供了重要机会。在这篇综述中，作者批判性地分析了支持使用各种干细胞来源的基础科学和转化证据，包括诱导多能干细胞、少突胶质前体细胞和间充质干细胞。随后，他们探讨了干细胞生物学的最新进展，并讨论了正在进行的临床转化努力，包括利用支架、生物凝胶和生长因子来增强干细胞存活、功能和植入的组合策略。最后，作者通过概述已完成的 (n = 18) 和正在进行的 (n = 9) 临床试验，讨论了 SCI 干细胞治疗的演变。
